NCT00665639

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 454 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy and safety of daily doses of IV micafungin versus IV caspofungin for the treatment of esophageal candidiasis

Conditions

• Candidiasis, Oral

Interventions

Type	Name	Description
DRUG	micafungin	IV
DRUG	caspofungin	IV

Timeline

• Start date: 2004-06-01
• Primary completion: 2004-12-01
• Completion: 2004-12-01
• First posted: 2008-04-24
• Last updated: 2014-08-20

Locations

31 sites across 4 countries: Argentina, Brazil, Peru, South Africa